NCT07752875尚未招募1 期
A Phase 1/2, Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation
LG Chem0 个研究点目标入组 250 人开始时间: 2026年12月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 250
- 主要终点
- Phase 1: Frequency of treatment-emergent adverse events (TEAEs)
研究概览
简要总结
This is a first-in-human, Phase 1/2, open-label study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of LG00313112 in participants with advanced solid malignancies harboring a TP53 Y220C mutation
详细描述
The objective of Phase 1 is to determine the biologically active dose range/maximum-tolerated dose (MTD) and/or recommended Phase 2 dose(s) (RP2D) of LG00313112 and to characterize the safety and tolerability of LG00313112.
The objective of Phase 2 is to evaluate the antitumor activity, safety, and tolerability of LG00313112 at the dose levels selected based on the Phase 1 results.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Males and females aged 18 years or older
- •Diagnosed locally advanced unresectable or metastatic solid tumor with a TP53 Y220C mutation.
- •Documented disease progression during or after the most recent line of therapy. In addition, must be refractory to or intolerant of standard of care therapy or have no standard therapy.
- •Measurable disease per RECIST v1.
- •Eastern Cooperative Oncology Group (ECOG) performance status 0-
- •Adequate organ function.
排除标准
- •Investigational therapy or anti-cancer therapy within 21 days or 5 half-lives prior to the first dose of study drug.
- •Radiotherapy within 14 days prior to the first dose of study drug.
- •Known brain metastases (Exception: Brain metastases are permitted if the participant is neurologically stable), leptomeningeal disease or carcinomatous meningitis.
- •Uncontrolled pleural effusion, pericardial effusion, or ascites.
- •History of myocardial infarction or unstable angina within 6 months prior to enrollment, or clinically significant cardiac disease
- •Serious infections requiring intravenous antibiotics within 14 days of first dose of study drug.
- •Active uncontrolled Hepatitis B, Hepatitis C, or human immunodeficiency virus infection
- •Acute or chronic uncontrolled renal disease, pancreatitis, or liver disease
- •History of prior organ transplant
- •Currently receiving strong Cytochrome P4503A (CYP3A4) inhibitors or inducers
研究组 & 干预措施
Dose escalation and Backfill
Experimental
干预措施: LG00313112 (Drug)
结局指标
主要结局
Phase 1: Frequency of treatment-emergent adverse events (TEAEs)
时间窗: Up to 12 months after treatment initiation
Phase 1: Number of participants with dose-limiting toxicities (DLTs)
时间窗: Up to 21 days after treatment
Phase 1: Frequency of serious adverse events (SAEs)
时间窗: Up to 12 months after treatment initiation
Phase 2: objective response rate (ORR)
时间窗: Up to 12 months after treatment initiation
次要结局
- Phase 1: Time to maximum observed plasma concentration (Tmax)(Approximately 12 months per participant (Approximately 77 months for Phase 1 and Phase 2))
- Phase 1: Maximum observed plasma concentration (Cmax)(Approximately 12 months per participant (Approximately 77 months for Phase 1 and Phase 2))
- Phase 1: Area under the concentration-time curve from time zero to time of last quantifiable concentration or in one dosing interval (AUC0-T, AUCtau)(Approximately 12 months per participant (Approximately 77 months for Phase 1 and Phase 2))
- Phase 1: Terminal half-life (T1/2)(Approximately 12 months per participant (Approximately 77 months for Phase 1 and Phase 2))
- Phase 1: ORR(Approximately 12 months per participant (Approximately 77 months for Phase 1 and Phase 2))
- Phase 1: Time to Response (TTR)(Approximately 12 months per participant (Approximately 77 months for Phase 1 and Phase 2))
- Phase 1: Duration of response (DOR)(Approximately 12 months per participant (Approximately 77 months for Phase 1 and Phase 2))
- Phase 1: Disease Control Rate (DCR)(Approximately 12 months per participant (Approximately 77 months for Phase 1 and Phase 2))
- Phase 1: Progression-free survival (PFS)(Approximately 12 months per participant (Approximately 77 months for Phase 1 and Phase 2))
- Phase 2: Frequency of TEAEs(Approximately 12 months per participant (Approximately 77 months for Phase 1 and Phase 2))
- Phase 2: Frequency of SAEs(Approximately 12 months per participant (Approximately 77 months for Phase 1 and Phase 2))
- Phase 2: DOR(Approximately 12 months per participant (Approximately 77 months for Phase 1 and Phase 2))
- Phase 2: DCR(Approximately 12 months per participant (Approximately 77 months for Phase 1 and Phase 2))
- Phase 2: PFS(Approximately 12 months per participant (Approximately 77 months for Phase 1 and Phase 2))
- Phase 2: Overall survival (OS)(Approximately 12 months per participant (Approximately 77 months for Phase 1 and Phase 2))
研究者
相似试验
招募中
1 期
A Phase I Trial of GW01-200 Tablets in Subjects With Advanced TumorsNCT07629258Groovy Medicine (Hangzhou) Ltd.100
招募中
1 期
Study of Intrathecal ELP-02 for Charcot-Marie-Tooth Disease Type 4J (CMT4J)NCT07447557Elpida Therapeutics SPC8
尚未招募
1 期
Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell LymphomaNCT07601607Sun Yat-sen University51
招募中
1 期
A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients.CRCNCT07283367Hansoh BioMedical R&D Company502
招募中
1 期
A First-in-human Study of KT502 in Adult Participants With Rheumatoid Arthritis (RA)Rheumatoid Arthritis (RA)NCT07564154Kali Therapeutics, Inc.27